Overview Financials News + Filings Key Docs Charts Ownership Insiders |
BSD Medical Corp (BSDMC)
|
Add to portfolio |
|
|
Price: |
$0.07
| | Metrics |
OS: |
9.77
|
M
| |
|
|
Market cap: |
$683.6
|
k
| |
-4436
|
% ROIC
|
Net cash:
|
$2.97
|
M
| |
$0.30
|
per share
|
EV:
|
|
| | | |
| | | | | |
TTM Valuation | | | |
EBITDA
|
($12.3)
|
M
| |
|
|
EBIT
|
($12.4)
|
M
| |
|
|
EPS |
($0.38)
| |
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
In millions, except per share items | Dec-31-14 | Aug-31-14 | Dec-31-13 | Aug-31-13 | Dec-31-12 | Aug-31-12 | Dec-31-11 | Aug-31-11 |
Revenues | 1.1 | 7.6 | 1.7 | 5.2 | 2.1 | 3.0 | 3.0 | 4.4 |
Revenue growth | -33.7% | 45.2% | -18.7% | 75.6% | -31.8% | -33.3% | | 55.7% |
Cost of goods sold | 0.6 | 2.9 | 0.8 | 2.3 | 1.5 | 1.5 | 1.7 | 1.7 |
Gross profit | 0.5 | 4.7 | 0.9 | 2.9 | 0.6 | 1.5 | 1.3 | 2.7 |
Gross margin | 46.6% | 61.8% | 52.1% | 56.6% | 26.8% | 48.9% | 43.6% | 61.5% |
Selling, general and administrative | 2.8 | 7.3 | 2.2 | 7.4 | 6.2 | 6.2 | 5.2 | 5.2 |
Research and development | 0.6 | | 0.7 | | 2.4 | | 1.5 | |
EBITA | -3.7 | -7.1 | -2.1 | -8.3 | -8.0 | -8.0 | -5.3 | -5.3 |
EBITA margin | -334.4% | -94.5% | -125.3% | -158.7% | -386.9% | -269.4% | -176.1% | -119.7% |
Amortization of intangibles | | | | 0.0 | | 0.0 | | 0.0 |
EBIT | -3.7 | -7.1 | -2.1 | -8.3 | -8.0 | -8.0 | -5.3 | -5.3 |
EBIT margin | -334.4% | -94.5% | -125.3% | -158.8% | -386.9% | -270.1% | -176.1% | -120.3% |
Pre-tax income | -3.8 | -7.1 | -2.1 | -8.2 | -8.0 | -8.0 | -5.3 | -5.3 |
Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
|
Diluted EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Shares outstanding (diluted) | 39.7 | 35.0 | 34.0 | 31.4 | 29.7 | 29.7 | 28.8 | 28.8 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|